Immunomic Therapeutics, a biotechnology company developing a new type of vaccine based on Johns Hopkins research, has reached a $300 million deal licensing its technology to Japanese company Astellas Pharma.
Astellas will be able to use Immunomic's vaccine design to develop products that treat or prevent allergic diseases under the deal. Immunomic will receive an up-front $300 million payment and then 10 percent royalties on sales Astellas gets using the technology. It also retains the rights to use its vaccine methods on other types of diseases, including cancer.